A Pilot Study of Temsirolimus and Body Composition

Overview

Journal J Cachexia Sarcopenia Muscle

Date 2013 Jul 30

PMID 23893509

Citations 13

Authors

Heloisa Veasey-Rodrigues

Henrique A Parsons

Filip Janku

Aung Naing

Jennifer J Wheler

Apostolia M Tsimberidou

Razelle Kurzrock

Affiliations

Soon will be listed here.

Abstract

Purpose: Body weight and composition play a role in cancer etiology, prognosis, and treatment response. Therefore, we analyzed the weight, body composition changes, and outcome in patients treated with temsirolimus, an mTor inhibitor that has weight loss as one of its side effects.

Patients And Methods: Sixteen patients with advanced solid tumors treated with temsirolimus were studied; body composition was evaluated utilizing computerized tomography images. Sarcopenia was defined as skeletal muscle index lower than 38.5 cm(2)/m(2) for women and 52.4 cm(2)/m(2) for men.

Results: Five of 16 patients (31 %) were men; median age, 60 years. Forty-four percent (7/16) of patients were sarcopenic. Fatigue, anemia, hyperglycemia, and hyperlipidemia were common. Baseline sarcopenia and body composition did not correlate with worse toxicity or treatment outcome. However, there was a trend for greater loss of adipose area (p = 0.07), fat mass (p = 0.09), and adipose index (p = 0.07) for patients with grade 3 or 4 toxicities versus those with grade 1 and 2 side effects.

Conclusion: Patients with higher grade toxicities tended to lose more body fat, suggesting a possible end-organ metabolic effect of temsirolimus. These observations merit exploration in a larger cohort of patients.

Citing Articles

The Current Landscape of Pharmacotherapies for Sarcopenia.

Bahat G, Ozkok S Drugs Aging. 2024; 41(2):83-112.

PMID: 38315328 DOI: 10.1007/s40266-023-01093-7.

Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.

Yuan Q, Hu J, Yuan F, An J PLoS One. 2023; 18(6):e0288077.

PMID: 37390088 PMC: 10313011. DOI: 10.1371/journal.pone.0288077.

Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.

Couderc A, Liuu E, Boudou-Rouquette P, Poisson J, Frelaut M, Montegut C Nutrients. 2023; 15(5).

PMID: 36904192 PMC: 10005339. DOI: 10.3390/nu15051193.

The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review.

Lin H, Salech F, Lim A, Vogrin S, Duque G Aging Clin Exp Res. 2022; 34(10):2317-2333.

PMID: 35861940 PMC: 9637607. DOI: 10.1007/s40520-022-02190-0.

The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels.

Oflazoglu U, Caglar S, Yilmaz H, Onal H, Varol U, Salman T Eur Geriatr Med. 2022; 13(4):795-803.

PMID: 35277853 DOI: 10.1007/s41999-022-00635-3.

References

Houde V, Brule S, Festuccia W, Blanchard P, Bellmann K, Deshaies Y . Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010; 59(6):1338-48. PMC: 2874694. DOI: 10.2337/db09-1324. View

Bhojani N, Jeldres C, Patard J, Perrotte P, Suardi N, Hutterer G . Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2007; 53(5):917-30. DOI: 10.1016/j.eururo.2007.11.037. View

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

Tang P, Heng D, Choueiri T . Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist. 2011; 16(11):1484-6. PMC: 3233281. DOI: 10.1634/theoncologist.2011-0337. View

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

Prado C, Baracos V, McCargar L, Reiman T, Mourtzakis M, Tonkin K . Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8):2920-6. DOI: 10.1158/1078-0432.CCR-08-2242. View

Mitsiopoulos N, Baumgartner R, Heymsfield S, Lyons W, Gallagher D, Ross R . Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985). 1998; 85(1):115-22. DOI: 10.1152/jappl.1998.85.1.115. View

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

Bodine S, Stitt T, Gonzalez M, Kline W, Stover G, Bauerlein R . Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001; 3(11):1014-9. DOI: 10.1038/ncb1101-1014. View

10.

Vogt P . PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med. 2001; 7(11):482-4. DOI: 10.1016/s1471-4914(01)02161-x. View

11.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

12.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View

13.

Tan B, Birdsell L, Martin L, Baracos V, Fearon K . Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15(22):6973-9. DOI: 10.1158/1078-0432.CCR-09-1525. View

14.

Kwak E, Bang Y, Camidge D, Shaw A, Solomon B, Maki R . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18):1693-703. PMC: 3014291. DOI: 10.1056/NEJMoa1006448. View

15.

Aslani A, Smith R, Allen B, Pavlakis N, LEVI J . The predictive value of body protein for chemotherapy-induced toxicity. Cancer. 2000; 88(4):796-803. DOI: 10.1002/(sici)1097-0142(20000215)88:4<796::aid-cncr10>3.0.co;2-p. View

16.

Chow W, McLaughlin J, Mandel J, Wacholder S, Niwa S, Fraumeni Jr J . Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5(1):17-21. View

17.

Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

18.

Antoun S, Birdsell L, Sawyer M, Venner P, Escudier B, Baracos V . Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010; 28(6):1054-60. DOI: 10.1200/JCO.2009.24.9730. View

19.

Murthy N, Mukherjee S, Ray G, Ray A . Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med. 2009; 55(1):45-54. DOI: 10.4103/0022-3859.43549. View

20.

Antoun S, Baracos V, Birdsell L, Escudier B, Sawyer M . Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21(8):1594-1598. DOI: 10.1093/annonc/mdp605. View